The FDA has approved Dato-DXd to treat certain advanced-stage hormone receptor-positive, HER2-negative breast cancers.

2024年4月23日 · Datopotamab deruxtecan (Dato-DXd) is a TROP2-directed ADC comprising a humanized anti-TROP2 immunoglobulin G1 monoclonal antibody covalently linked to a highly potent topoisomerase I (topo I) inhibitor, a derivative of exatecan, via a plasma-stable, tumor-selective, tetrapeptide-based cleavable linker, resulting in reduced systemic exposure and ...

On January 17, 2025, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.), a Trop-2-directed antibody and topoisomerase inhibitor conjugate, for ...

2024年5月27日 · Datopotamab deruxtecan is a specifically engineered TROP2-directed DXd antibody drug conjugate discovered by Daiichi Sankyo and being jointly developed by AstraZeneca and Daiichi Sankyo.

2021年8月21日 · Dato-DXd exhibited in vivo antitumor activity with DNA damage induced by the accumulated DXd in TROP2-expressing xenograft tumors, but neither isotype control IgG-ADC nor anti-TROP2 antibody had this effect. Dato-DXd also showed potent antitumor activity with tumor regression in several TROP2-expressing xenograft tumors including NSCLC PDX models.

2025年1月17日 · Designed using Daiichi Sankyo’s proprietary DXd ADC Technology, Datroway is one of six DXd ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programmes in AstraZeneca’s ADC scientific platform.

2025年2月18日 · Background: Dato-DXd is a TROP2-directed antibody-drug conjugate under investigation in various solid tumor types. We report updated results in patients (pts) with locally advanced/metastatic urothelial cancer (la/m UC) from the ongoing phase 1 TROPION-PanTumor01 study (NCT03401385).

2025年1月17日 · FDA approved Dato-DXd for HR-positive, HER2-negative breast cancer after prior endocrine and chemotherapy treatments. Phase 3 TROPION-Breast-01 trial demonstrated improved progression-free and overall survival with Dato-DXd.

Clinical trial number NCT05104866 for "A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)" at ClinicalTrials.gov

2023年9月22日 · Datopotamab deruxtecan (Dato-DXd) is an investigational TROP2-directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, datopotamab deruxtecan is one of five lead ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programmes in AstraZeneca’s ADC scientific platform.